A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors

Background To determine the recommended phase II dose (RP2D) and assess the safety, pharmacokinetics (PKs) and pharmacodynamics of RO4929097in combination with temsirolimus. Methods Escalating doses of RO4929097 and temsirolimus were administered at three dose levels. Patients received once daily or...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Diaz-Padilla, Ivan, Hirte, Hal, Oza, Amit M., Clarke, Blaise A., Cohen, Brenda, Reedjik, Michael, Zhang, Tong, Kamel-Reid, Suzanne, Ivy, S. Percy, Hotte, Sebastien J., Razak, Albiruni A. R., Chen, Eric X., Brana, Irene, Wizemann, Monika, Wang, Lisa, Siu, Lillian L., Bedard, Philippe L.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer US 2013
Soggetti:
Phase I Studies
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3771370/
https://ncbi.nlm.nih.gov/pubmed/23860641
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-013-0001-5
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi